MRK: Merck & Co., Inc. - Summary | Jitta

Merck & Co., Inc.

NYSE:MRK

Price
$71.97
Loss Chance
42.4%
6.99JITTA SCORE
11.36%Under Jitta Line
Jitta Ranking
5 / 1,076
179 / 4,656
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (74)
Recent Business Performance (69)
Financial Strength (59)
Return to Shareholders (92)
Competitive Advantage (76)
Jitta Signs
Revenue and EarningConsistent
Debt LevelLow Long Term Debt
Share RepurchaseEvery Year
Interest Coverage RatioVery Good
SG&A to SalesDecreasing
Recent Business PerformanceEarning decline 1.30% in the last year
Key Stats
Jitta Score
Jitta Line
6.99
11.36%
2.04
285.61%
2.25
311.78%
Pharmaceuticals
5.03
63.23%
5.61
23.18%
3.76
71.56%
COMPANY DESCRIPTION
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women’s health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology and autoimmunity (intestinal epithelial barrier in autoimmune diseases); NGM Biopharmaceuticals, Inc. to focus primarily on the development of medicines in retinal and CVM diseases; and to develop and commercialize tests that identify genetic mutations, as well as with IO Biotech ApS to evaluate IO102-IO103. It also has a partnership with Biocorp Production for the development and supply of a specific version of Mallya device. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.